Marksans Pharma Limited (NSE:MARKSANS)
222.00
-2.14 (-0.95%)
Mar 28, 2025, 3:30 PM IST
Marksans Pharma Revenue
Marksans Pharma had revenue of 6.82B INR in the quarter ending December 31, 2024, with 16.33% growth. This brings the company's revenue in the last twelve months to 24.74B, up 17.64% year-over-year. In the fiscal year ending March 31, 2024, Marksans Pharma had annual revenue of 21.77B with 17.56% growth.
Revenue (ttm)
24.74B
Revenue Growth
+17.64%
P/S Ratio
4.07
Revenue / Employee
21.69M
Employees
1,141
Market Cap
100.82B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 21.77B | 3.25B | 17.56% |
Mar 31, 2023 | 18.52B | 3.61B | 24.23% |
Mar 31, 2022 | 14.91B | 1.15B | 8.33% |
Mar 31, 2021 | 13.76B | 2.42B | 21.32% |
Mar 31, 2020 | 11.34B | 1.34B | 13.43% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Marksans Pharma News
- 11 days ago - Marksans Pharma shares up nearly 4% as company secures Australian TGA approval for Goa facility - Business Upturn
- 11 days ago - Marksans Pharma’s Goa facility gets Australian TGA approval for Solid Dosage manufacturing - Business Upturn
- 12 days ago - Marksans Pharma’s subsidiary Relonchem receives marketing authorization from UK MHRA for Baclofen 10 mg tablets - Business Upturn
- 4 weeks ago - Marksans Pharma’s subsidiary Relonchem gets UK approval for Ibuprofen and Paracetamol tablets - Business Upturn
- 4 months ago - Marksans Pharma shares jump 2% following USFDA approval for Loratadine Tablets USP 10 mg - Business Upturn
- 4 months ago - Marksans Pharma receives USFDA approval for Loratadine Tablets USP 10 mg - Business Upturn
- 4 months ago - Marksans Pharma Ltd (BOM:524404) Q2 FY25 Earnings Call Highlights: Strong Revenue Growth and ... - GuruFocus
- 4 months ago - Marksans Pharma shares jump over 3% on Q2 results - Business Upturn